Clinical trials: Next-generation Sequencing
- Condition Next-generation Sequencing
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Encephalitis
SouthEast Asia Encephalitis Project
Encephalitis, an acute inflammation of the central nervous system associated with neurologic dysfunction is of public health concern worldwide, because of its high mortality and neurological sequelae rates.
- Trial name
- SEAe (NCT04089436)
- Testing
- CSF sampling, Blood sampling, Nasopharyngeal and rectal sampling
- Where
- 7 sites in Burma, Cambodia and 2 more
- Volunteers
- 800 people
- Sponsor
- Institut Pasteur
Infection, Meningitis
Pediatric Infectious Disease Precision Medicine Using Sequencing Evaluation of CSF
Prospective, multi-site, study to evaluate the diagnosis rate of DNA and RNA sequencing of cerebrospinal fluid for identification of pathogens directly in patients who have already had a spinal tap to evaluate for infection and…
- Trial name
- PIPSEC (NCT03796546)
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- IDbyDNA, Inc.
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Central Nervous System Infection
Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection
Delve Bio, Inc. is a developer of novel mNGS tests with the goal of aiding in the diagnosis of infectious diseases in several clinical indications that may not have alternative traditional diagnostic methods routinely available.
- Trial name
- IMPACT (NCT07435649)
- Testing
- Delve Detect CSF mNGS Test, Real-World Data
- Where
- 6 sites in United States
- Volunteers
- 400 people
- Sponsor
- Delve Bio, Inc.